Abstract
Background: Angiotensin converting enzyme 2 (ACE2) is an integral membrane protein thought to be a protective factor in the development of heart failure (HF) by antagonizing the actions of angiotensin II. However, relatively little is known about human ACE2, due in part to the need for invasive cardiac tissue sampling. Methods and Results: We developed a sensitive and specific assay to measure soluble ACE2 (sACE2) activity in plasma using specific ACE2 inhibitors. sACE2 activity was screened in patients admitted to the Cleveland Clinic who had a B-type natriuretic peptide (BNP) drawn for any reason.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
